Non-invasive prenatal testing (NIPT) is a screening method used during pregnancy to identify the risk of certain chromosomal abnormalities in the developing fetus. This testing involves analyzing cell-free fetal DNA found in the pregnant person’s blood. The test provides an assessment of risk for conditions such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). It differs from diagnostic tests like amniocentesis or chorionic villus sampling (CVS), which are more invasive but provide a definitive diagnosis.
Access to prenatal care, including advanced screening options, plays a significant role in informed reproductive health decisions. These tests can alleviate anxieties, provide time for preparation, and inform further diagnostic testing options when necessary. Historically, more invasive procedures were the only options available for prenatal genetic screening, carrying a small but real risk of miscarriage. The advent of non-invasive methods significantly improved the safety profile of prenatal screening.